

NUT Midline Carcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy), By Route Of Administration (Oral), By End Use, By Region, And Segment Forecasts, 2024 - 2030

<https://marketpublishers.com/r/NF17BF4C8AB2EN.html>

Date: September 2024

Pages: 120

Price: US\$ 5,950.00 (Single User License)

ID: NF17BF4C8AB2EN

Abstracts

This report can be delivered to the clients within 3 Business Days

Nuclear Medicine Equipment Market Growth & Trends

The global nuclear medicine equipment market size is expected to reach a value of USD 8.47 billion by 2030 and is projected to grow at a CAGR of 3.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Nuclear medicine involves the utilization of radiation to diagnose diseases or treat them. It also involves determining whether specific organs are functioning normally. Over a stretch of the last two decades, rapid technological advancements in nuclear medicine have transformed the medicine practice.

With growing awareness about the importance of early diagnosis of chronic diseases, there has been a noticeable increase in diagnostic nuclear medicine procedures worldwide. This is evident from stats generated from developing countries, which represents about 26% of the world population. These countries conduct diagnostic nuclear medicine tests at a rate of 1.9% per year. In addition, in developed countries such as the U.S., the frequency of nuclear medicine procedures ranges to about 20 million per year. It is evident that the frequency of use of nuclear medicine and procedures involving radiopharmaceuticals in diagnosis is growing at over 10% per year, indicating a rise in adoption of nuclear medicine equipment worldwide. However, high cost associated with nuclear medicine equipment and insufficient reimbursement

support for radiology is expected to hinder the growth of the market. In addition, a growing trend of purchasing refurbished systems for cost saving is expected to affect equipment sales of existing market players.

Nuclear Medicine Equipment Market Report Highlights

The North American market is expected to register lucrative growth owing to increasing preference for SPECT and PET scans for diagnosis of chronic diseases

Growing awareness and government initiatives pertaining to usage of radiopharmaceuticals in the North American region is expected to boost usage rates. For instance, in December 2016, the FDA issued new guidelines to enforce FDA's proposed policies regarding compounding and repackaging of radiopharmaceuticals for human use in the U.S.

Oncology accounted for the largest market share in application segment in the year 2023 owing to the increasing incidence and prevalence of cancer worldwide

Asia Pacific market is expected to witness significant growth owing to Japan, China, and India where use of nuclear medicine is increasing at a fast pace. In addition, the usage of radioimmunotherapy-based targeted cancer treatment to counter incidence of cancer and cardiovascular diseases is aiding in the growth of the market

The key players are focused on expansion & penetration opportunities in developing and emerging economies to achieve sustainable growth in the market

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Treatment
 - 1.2.2. Route of Administration
 - 1.2.3. End Use
 - 1.2.4. Regional scope
 - 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased database
 - 1.4.2. GVR's internal database
 - 1.4.3. Secondary sources
 - 1.4.4. Primary research
 - 1.4.5. Details of primary research
 - 1.4.5.1. Data for primary interviews in North America
 - 1.4.5.2. Data for primary interviews in Europe
 - 1.4.5.3. Data for primary interviews in Asia Pacific
 - 1.4.5.4. Data for primary interviews in Latin America
 - 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
 - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity flow analysis (Model 1)
 - 1.7.2. Approach 1: Commodity flow approach
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
 - 2.2.1. Treatment Outlook
 - 2.2.2. Route of Administration

- 2.2.3. End Use
- 2.2.4. Regional outlook
- 2.3. Competitive Insights

CHAPTER 3. NUT MIDLINE CARCINOMA TREATMENT MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent market outlook
 - 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
 - 3.2.1. Market driver analysis
 - 3.2.1.1. Rising Prevalence NUT Midline Carcinoma
 - 3.2.1.2. Advancement in Diagnostics
 - 3.2.2. Market restraint analysis
 - 3.2.2.1. High Diagnostic Challenges
 - 3.2.2.2. Limited Awareness
- 3.3. NUT midline carcinoma Treatment Market Analysis Tools
 - 3.3.1. Industry Analysis – Porter's
 - 3.3.1.1. Supplier power
 - 3.3.1.2. Buyer power
 - 3.3.1.3. Substitution threat
 - 3.3.1.4. Threat of new entrant
 - 3.3.1.5. Competitive rivalry
 - 3.3.2. PESTEL Analysis
 - 3.3.2.1. Political landscape
 - 3.3.2.2. Technological landscape
 - 3.3.2.3. Economic landscape

CHAPTER 4. NUT MIDLINE CARCINOMA TREATMENT MARKET: TREATMENT ESTIMATES & TREND ANALYSIS

- 4.1. Global NUT midline carcinoma Treatment Market: Treatment Dashboard
- 4.2. Global NUT midline carcinoma Treatment Market: Treatment Movement Analysis
- 4.3. Global NUT midline carcinoma Treatment Market by Treatment, Revenue
- 4.4. Chemotherapy
 - 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Targeted Therapy
 - 4.5.1. Targeted Therapy market estimates and forecasts 2018 to 2030 (USD Million)

4.6. Immunotherapy

4.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)

4.7. Radiation Therapy

4.7.1. Radiation Therapy market estimates and forecasts 2018 to 2030 (USD Million)

4.8. Others

4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 5. NUT MIDLINE CARCINOMA TREATMENT MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS

5.1. Global NUT midline carcinoma Treatment Market: Route of Administration Dashboard

5.2. Global NUT midline carcinoma Treatment Market: Route of Administration Movement Analysis

5.3. Global NUT midline carcinoma Treatment Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)

5.4. Oral

5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

5.5. Intravenous

5.5.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)

5.6. Other

5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 6. NUT MIDLINE CARCINOMA TREATMENT MARKET: END USE ESTIMATES & TREND ANALYSIS

6.1. Global NUT midline carcinoma Treatment Market: End Use Dashboard

6.2. Global NUT midline carcinoma Treatment Market: End Use Movement Analysis

6.3. Global NUT midline carcinoma Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)

6.4. Hospitals

6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)

6.5. Specialty Clinics

6.5.1. Specialty clinics market estimates and forecasts 2018 to 2030 (USD Million)

6.6. Other

6.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 7. NUT MIDLINE CARCINOMA TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

7.1. Regional Dashboard

7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:

7.3. North America

7.3.1. U.S.

7.3.1.1. Key country dynamics

7.3.1.2. Regulatory framework/ reimbursement structure

7.3.1.3. Competitive scenario

7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)

7.3.2. Canada

7.3.2.1. Key country dynamics

7.3.2.2. Regulatory framework/ reimbursement structure

7.3.2.3. Competitive scenario

7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)

7.3.3. Mexico

7.3.3.1. Key country dynamics

7.3.3.2. Regulatory framework/ reimbursement structure

7.3.3.3. Competitive scenario

7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)

7.4. Europe

7.4.1. UK

7.4.1.1. Key country dynamics

7.4.1.2. Regulatory framework/ reimbursement structure

7.4.1.3. Competitive scenario

7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)

7.4.2. Germany

7.4.2.1. Key country dynamics

7.4.2.2. Regulatory framework/ reimbursement structure

7.4.2.3. Competitive scenario

7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)

7.4.3. France

7.4.3.1. Key country dynamics

7.4.3.2. Regulatory framework/ reimbursement structure

7.4.3.3. Competitive scenario

7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)

7.4.4. Italy

7.4.4.1. Key country dynamics

7.4.4.2. Regulatory framework/ reimbursement structure

7.4.4.3. Competitive scenario

- 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.5. Spain
 - 7.4.5.1. Key country dynamics
 - 7.4.5.2. Regulatory framework/ reimbursement structure
 - 7.4.5.3. Competitive scenario
 - 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.6. Norway
 - 7.4.6.1. Key country dynamics
 - 7.4.6.2. Regulatory framework/ reimbursement structure
 - 7.4.6.3. Competitive scenario
 - 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.7. Sweden
 - 7.4.7.1. Key country dynamics
 - 7.4.7.2. Regulatory framework/ reimbursement structure
 - 7.4.7.3. Competitive scenario
 - 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.8. Denmark
 - 7.4.8.1. Key country dynamics
 - 7.4.8.2. Regulatory framework/ reimbursement structure
 - 7.4.8.3. Competitive scenario
 - 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Asia Pacific
 - 7.5.1. Japan
 - 7.5.1.1. Key country dynamics
 - 7.5.1.2. Regulatory framework/ reimbursement structure
 - 7.5.1.3. Competitive scenario
 - 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.5.2. China
 - 7.5.2.1. Key country dynamics
 - 7.5.2.2. Regulatory framework/ reimbursement structure
 - 7.5.2.3. Competitive scenario
 - 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.5.3. India
 - 7.5.3.1. Key country dynamics
 - 7.5.3.2. Regulatory framework/ reimbursement structure
 - 7.5.3.3. Competitive scenario
 - 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.5.4. Australia
 - 7.5.4.1. Key country dynamics

- 7.5.4.2. Regulatory framework/ reimbursement structure
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. South Korea
 - 7.5.5.1. Key country dynamics
 - 7.5.5.2. Regulatory framework/ reimbursement structure
 - 7.5.5.3. Competitive scenario
 - 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Thailand
 - 7.5.6.1. Key country dynamics
 - 7.5.6.2. Regulatory framework/ reimbursement structure
 - 7.5.6.3. Competitive scenario
 - 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Latin America
 - 7.6.1. Brazil
 - 7.6.1.1. Key country dynamics
 - 7.6.1.2. Regulatory framework/ reimbursement structure
 - 7.6.1.3. Competitive scenario
 - 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.6.2. Argentina
 - 7.6.2.1. Key country dynamics
 - 7.6.2.2. Regulatory framework/ reimbursement structure
 - 7.6.2.3. Competitive scenario
 - 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. MEA
 - 7.7.1. South Africa
 - 7.7.1.1. Key country dynamics
 - 7.7.1.2. Regulatory framework/ reimbursement structure
 - 7.7.1.3. Competitive scenario
 - 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.7.2. Saudi Arabia
 - 7.7.2.1. Key country dynamics
 - 7.7.2.2. Regulatory framework/ reimbursement structure
 - 7.7.2.3. Competitive scenario
 - 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.7.3. UAE
 - 7.7.3.1. Key country dynamics
 - 7.7.3.2. Regulatory framework/ reimbursement structure
 - 7.7.3.3. Competitive scenario

7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

7.7.4. Kuwait

7.7.4.1. Key country dynamics

7.7.4.2. Regulatory framework/ reimbursement structure

7.7.4.3. Competitive scenario

7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Company/Competition Categorization

8.2. Vendor Landscape

8.2.1. List of key distributors and channel partners

8.2.2. Key company market share analysis, 2023

8.2.3. Merck & Co. Inc

8.2.3.1. Company overview

8.2.3.2. Financial performance

8.2.3.3. Product benchmarking

8.2.3.4. Strategic initiatives

8.2.4. Bristol-Myers Squibb Company

8.2.4.1. Company overview

8.2.4.2. Financial performance

8.2.4.3. Product benchmarking

8.2.4.4. Strategic initiatives

8.2.5. Pfizer Inc.

8.2.5.1. Company overview

8.2.5.2. Financial performance

8.2.5.3. Product benchmarking

8.2.5.4. Strategic initiatives

8.2.6. F. Hoffmann-La Roche Ltd

8.2.6.1. Company overview

8.2.6.2. Financial performance

8.2.6.3. Product benchmarking

8.2.6.4. Strategic initiatives

8.2.7. C4 Therapeutics, Inc.

8.2.7.1. Company overview

8.2.7.2. Financial performance

8.2.7.3. Product benchmarking

8.2.7.4. Strategic initiatives

8.2.8. Ipsen Biopharmaceuticals, Inc

- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. GSK plc
 - 8.2.9.1. Company overview
 - 8.2.9.2. Financial performance
 - 8.2.9.3. Product benchmarking
 - 8.2.9.4. Strategic initiatives

I would like to order

Product name: NUT Midline Carcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy), By Route Of Administration (Oral), By End Use, By Region, And Segment Forecasts, 2024 - 2030

Product link: <https://marketpublishers.com/r/NF17BF4C8AB2EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NF17BF4C8AB2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970